13F Pro quality score
Rank #2,806 of 2,925
Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.
Reported revenue, net income and operating margin by fiscal year, from Arcadia Biosciences, Inc.'s annual filings on SEC EDGAR.
| Period | Form | Revenue | Net income | Op. marginOperating margin |
|---|---|---|---|---|
| FY 2025 | 10-K | $4.9M | $-2.3M | -51.5% |
| FY 2024 | 10-K | $5.0M | $-7.0M | -72.3% |
| FY 2023 | 10-K | $4.5M | $-14.0M | -137.0% |
| FY 2022 | 10-K | $7.4M | $-15.4M | -188.8% |
| FY 2021 | 10-K | $6.8M | $-14.7M | — |
| FY 2020 | 10-K | $8.0M | $-4.7M | -159.1% |
Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.
Arcadia Biosciences, Inc. (RKDA) stock profile, AI quality score, and SEC EDGAR financial data, a Energy sector company. 13F Pro's AI-powered ranking engine scores RKDA at 15.9/100 on a composite quality score built from its SEC filings, placing it at rank #2,806 of 2,925 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Arcadia Biosciences, Inc. reports quarterly revenue of $1.4M, net income of $-6.3M, an operating margin of -34.4%. Top institutional holders of RKDA by reported 13-F value include HRT FINANCIAL, CITADEL ADVISORS, Virtu Financial, based on the most recent SEC filings. RKDA trades on the Nasdaq exchange and files with the SEC under CIK 1469443. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RKDA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Arcadia Biosciences, Inc. directly from SEC EDGAR.